Search results: (10000)
News Desirable Side Effects of Antidiabetics
The days when diabetology was a field solely focused on normalizing blood sugar levels are long gone. Today, the approach in diabetology increasingly prioritizes influencing the patient's overall life prognosis, particularly reducing cardiovascular risk. What can be the desirable side effects of the main groups of antidiabetics that are not related to merely lowering glucose levels?
News Recommendations for Lipid Administration in Patients on Home Parenteral Therapy
Home parenteral therapy is an important part of treatment for patients with chronic intestinal failure who cannot achieve adequate nutrition through enteral feeding. An integral component of this therapy is lipid emulsion, which provides a source of energy and essential fatty acids. However, long-term administration of lipid emulsion may be associated with liver damage. According to available studies, the risk can be reduced by adjusting the dosage of lipid emulsion and preferring emulsions without soybean oil.
News Stable Position of Micronized Diosmin in the Treatment of Chronic Venous Insufficiency and Hemorrhoids
Diosmin is a flavonoid used in Europe as a venotonic and vasoprotective agent for over 40 years. Significant progress has been made in medicine during this time, yet the role of diosmin in the treatment of venous insufficiency and hemorrhoidal disease remains important. Diosmin itself has also evolved, being micronized for better biological availability and showing significant effects on the vascular system according to research.
News ACC 2023 Expert Consensus: How to Optimize Diagnosis and Treatment of Heart Failure with Preserved EF LK
Heart failure (HF) remains a significant cause of morbidity and mortality, with the incidence and prevalence of HF with preserved left ventricular ejection fraction (HFpEF) rising. The following document focuses on individuals with HFpEF and supports the principles of evidence-based diagnosis and treatment of HF from 2022. It emphasizes the need for individualized care and multidisciplinary cooperation.
News CASE STUDY: Surgical Procedure in an Adolescent Patient with Severe Hemophilia A on Emicizumab Prophylaxis
This case study is narrated by MUDr. Bohumír Blažek from the Clinic of Pediatric Medicine at LF OU and FN Ostrava. The patient is a 17-year-old boy with severe hemophilia A. Several months prior to the procedure under discussion, he was switched from prophylactic factor VIII administration to emicizumab prophylaxis. Subsequently, an extraction of all four molars was planned for orthodontic reasons. The case study describes the hematologist's approach to the procedure and the subsequent healing process.
News Romiplostim in Life-Threatening Bleeding Situations − Case Reports
Immune thrombocytopenic purpura, or immune thrombocytopenia (ITP), typically manifests as bleeding due to a low platelet count. Some bleeding episodes can be life-threatening or fatal. Clinical experience suggests that in acute bleeding complications, whether in acute ITP or exacerbations of chronic ITP, early use of the thrombopoietin receptor agonist (TPO-RA) romiplostim can be beneficial. Japanese authors have described three case reports of severe diffuse alveolar hemorrhage (DAH) associated with various underlying conditions.
News Diosmin – Still an Important Modality in the Treatment of Venous Insufficiency
Chronic venous insufficiency is a highly prevalent disease in the Western population. Unfortunately, it remains without causal treatment. In the recommended therapeutic procedures, especially in the initial stages, compression treatment supplemented with pharmacotherapy plays a key role. This includes the administration of medicinal products containing micronized diosmin. The following text summarizes basic findings about its properties that predispose it to clinical use.
News Prevalence of Metabolic Syndrome During 1 Year After the First Episode of Psychosis
Portuguese authors elucidated the high prevalence of metabolic syndrome and adverse metabolic parameters in individuals with the first episode of psychosis. Moreover, it significantly increased during 1 year after this episode.
News Longer survival without liver transplant in patients with PBC treated with OCA?
Obeticholic acid (OCA) is a second-line treatment for patients with primary biliary cholangitis (PBC) who have an inadequate response to ursodeoxycholic acid (UDCA) or intolerance to it. The study presented below, the results of which were recently published, examined the effectiveness of OCA in reducing cholestatic enzymes as well as the length of survival without liver transplant in patients with PBC.
News What situations can arise in PBC treatment with obeticholic acid? Answers provided by case studies from real practice at CKTCH
The Hradec Gastroenterology Days 2023 were traditionally held in March at the Educational Center of the Faculty of Medicine, Charles University, in the area of University Hospital Hradec Králové. The expert program included a lecture by MUDr. Libuše Husová, Ph.D., from the Cardio-surgical and Transplant Surgery Center Brno (CKTCH), who highlighted various situations that can arise during the treatment of primary biliary cholangitis (PBC) with three case studies.
News Experiences with treating PBC with obeticholic acid in Brno's CKTCH
MUDr. Libuše Husová, Ph.D., shared the current insights from the therapy of patients with primary biliary cholangitis (PBC) using obeticholic acid (OCA) gained at the Center for Cardiovascular and Transplantation Surgery in Brno (CKTCH) during the XLVIII May Hepatology Days.
News Efficacy and Safety of Teriflunomide in the Treatment of Multiple Sclerosis in Children – Results of the TERIKIDS Study
Therapeutic options for multiple sclerosis in the pediatric population are limited. However, in June 2021, teriflunomide was approved for the treatment of relapsing-remitting multiple sclerosis (RRMS) in pediatric patients aged 10–17 years in the European Union. The basis for this registration was the favorable results of the TERIKIDS study, which we summarize below. Teriflunomide thus became the first oral medication for 1st line treatment of RRMS in children and adolescents within the EU.
News Current Insights into the Antispasmodic and Analgesic Effects of Metamizole on the Gastrointestinal Tract
Brazilian authors published a review of available information on the mechanism of action of metamizole, its impact on gastrointestinal tract motility, its effect on the gastric mucosa, and its antispasmodic effects.
News Current View on Prophylactic Negative Pressure Wound Therapy in Practice from Surgeons' Perspective
The journal Updates in Surgery recently published the results of a survey on prophylactic negative-pressure wound therapy (pNPWT) conducted among Swiss surgeons. The survey results show how often this therapy is used, in what situations it is typically applied, and what could make negative-pressure wound therapy more attractive in the future.
News Does Tofacitinib Improve Comorbid Depressive and/or Anxiety Symptoms in Patients with Rheumatoid Arthritis?
Depression and anxiety disorders are commonly observed in patients with rheumatoid arthritis and can lead to a reduction in quality of life, functional capacity, and, last but not least, to a lower therapeutic response. Therefore, the study presented below examined the prevalence of depressive and generalized anxiety disorders in clinical trials using tofacitinib and the effectiveness of tofacitinib according to baseline values of depression and anxiety.
News Can tofacitinib have a positive impact on the mental stress of patients with rheumatoid arthritis?
In the population of patients with rheumatoid arthritis (RA), there is a higher incidence of depression and anxiety compared to the healthy population. These psychiatric comorbidities can lead to a reduced quality of life and a poorer response to treatment. The aim of the post-hoc analysis presented below was to monitor the effect of tofacitinib on improving anxiety and depression in patients with RA.
News Is long-term treatment with ixekizumab sufficiently safe?
Psoriasis is a chronic inflammatory disease whose manifestations require long-term treatment. A poster presented at last year's European Academy of Dermatology and Venereology (EADV) congress summarizes ixekizumab safety data from monitoring lasting up to 5 years, based on nearly 18,000 patient-years (PY) in the treatment of this disease.
News Direct Oral Anticoagulants and Their Reversal Agents – Current Options
In the last 10 years, the options for anticoagulant therapy have expanded with the introduction of direct oral anticoagulants (DOACs). It appears that DOACs may soon replace warfarin in the first line of prevention of venous thromboembolism, not only due to their clinical advantages but also thanks to newly available reversal agents that can be administered in case of major bleeding in patients taking DOACs. A recently published review article summarizes the current situation in this area.
News Improving treatment outcomes of HF with preserved ejection fraction according to JACC: What does the success of gliflozins mean for the future?
The Journal of the American College of Cardiology (JACC) recently issued a scientific statement in which the authors thoroughly examined current knowledge on the epidemiology, pathophysiology, diagnosis, and treatment of heart failure with preserved ejection fraction of the left ventricle (HFpEF). Recent studies in this heterogeneous disease suggest the importance of carefully determining the HFpEF phenotype in a given patient based on pathophysiology, which enables better individualization of treatment. The authors also reflect on the success of gliflozins in treating HFpEF and how HFpEF pharmacotherapy can be further improved.
News Therapy of Chronic Leg Ulcers According to Evidence-Based Medicine
Chronic ulcers on the lower extremities are defined as trophic defects that show no signs of healing after 3 months of appropriate treatment or are not healed even after 12 months of treatment. Their incidence and prevalence are continuously increasing, and they currently represent not only a serious medical problem but also a socioeconomic issue. An overview article published by German physicians focuses on summarizing the therapy of leg ulcers according to the principles of evidence-based medicine.
News Drops with Liposomal Ozonized Oil Reduce Ocular Microbial Burden Before Cataract Surgery
The periocular zone and conjunctiva are characterized by high microbial activity. Therefore, it is important to reduce this bacterial burden as part of preoperative prophylaxis before surgery to minimize the risk of infection. The aim of the study presented below, conducted in 20 Italian centers, was to evaluate the antimicrobial efficacy of a new ocular solution in patients undergoing cataract surgery.
News Current News from ECCO 2023: Tofacitinib in the Treatment of Ulcerative Colitis in Real-World Practice
At the 18th ECCO Congress, held in March 2023 in Copenhagen, results from a Spanish real-world study were presented. This study evaluated the efficacy and safety of tofacitinib in the treatment of ulcerative colitis (UC), including the impact of this drug on extraintestinal manifestations of the disease and immune-mediated diseases.
News OHD 2024: What’s New in Data and Experiences from Real Practice with Venetoclax Regimens?
How to utilize venetoclax regimens most effectively for treating chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML) in real practice was the topic of a satellite symposium organized by AbbVie during this year’s XXXVIth Olomouc Hematology Days. Three hemato-oncologists shared their experiences with venetoclax treatment, moderated by Prof. MUDr. Tomáš Papajík, CSc., from the Department of Hemato-Oncology, Faculty of Medicine, Palacky University and University Hospital Olomouc.
News Sustained Remission of ITP with Thrombopoietin Receptor Agonists Treatment
Thrombopoietin receptor agonists (TPO-RAs) are highly effective drugs administered in chronic immune thrombocytopenia (ITP). Several studies have shown that they can induce remission and long-term response, even after prolonged discontinuation.
News Comparison of the Efficacy of Tofacitinib and Vedolizumab in the Treatment of Ulcerative Colitis After Anti-TNF Therapy Failure
Therapeutic options for ulcerative colitis resistant to anti-TNF-α antibody treatment are available, but there were no studies comparing the selective immunosuppressants tofacitinib and vedolizumab in this patient population. The aim of this comparison was a multicenter French study, the first results of which were presented at the 17th ECCO Congress 2022.